The MAQUET line of FUSION grafts merges ePTFE with PET to offer vascular surgeons the best of both materials: the easy handling of ePTFE and the minimal suture hole bleeding seen in knit polyester ...

Trusted for more than 20 years, HEMASHIELD grafts are the most used, most studied vascular products available in the market today. More than 2 million HEMASHIELD grafts have been implanted ...

Cite this: Technology Insight: The Evolution of Tissue-Engineered Vascular Grafts--From Research to Clinical Practice - Medscape - Jul 01, 2007. The recent transition to clinical use by two ...

A breakthrough in life-saving medical technology has arrived. The U.S. Food and Drug Administration (FDA) has officially ...

The contribution of vascular proliferation to the pathophysiology of in-stent restenosis, transplant vasculopathy and vein bypass graft failure is particularly important. Thus, an emerging ...

Humacyte stock has dropped 46% since July, mainly due to FDA review delays. Check out why I downgraded HUMA stock from "buy" ...

SYMVESS is a bioengineered human tissue designed as a vascular conduit for arterial replacement in adults facing imminent limb loss. How does SYMVESS compare to traditional vein grafts?

Benchmark analyst Bruce Jackson raised the firm’s price target on Humacyte (HUMA) to $17 from $15 and keeps a Buy rating on ...

The first acellular tissue engineered vessel for adults with vascular trauma in a bodily extremity has been approved by the U.S. FDA. Symvess, which comes from regenerative tissue developer Humacyte ...

The single-use product is surgically implanted for arterial replacement and repair after a traumatic injury to the extremity.